5-hydroxytryptamine (HT)1A receptors and the tail-flick response. II. High efficacy 5-HT1A agonists attenuate morphine-induced antinociception in mice in a competitive-like manner

MJ Millan and FC Colpaert

Neurobiology Division, Fondax, Groupe de Recherche Servier, Puteaux, France.

This study examined the influence of s.c. administration of 5- hydroxytryptamine (HT)1A agonists upon the antinociceptive action of s.c. injected morphine in tail-flick tests to noxious heat and pressure. The selective 5-HT1A agonist, (+-)-8-hydroxy- diprolaminotetralin HBr (8-OH-DPAT), dose-dependently antagonized morphine-induced antinociception (MIA) without affecting the latency to respond when applied alone. In the presence of increasing doses of 8-OH- DPAT (0.16-0.63 mg/kg), the morphine dose-response curve was shifted progressively in parallel to the right and the maximal effect of morphine was not altered; Schild analysis yielded a slope of close to - 1.0. 8-OH-DPAT both prevented and reversed the action of morphine. The action of 8-OH-DPAT was reversible (at 24 hr). In distinction, 8-OH- DPAT neither blocked morphine-induced Straub tail nor precipitated withdrawal in morphine-dependent animals; thus, it lacked opioid- antagonist properties. The antagonism of MIA by 8-OH-DPAT was mimicked by additional drugs acting as high efficacy 5-HT1A agonists: lisuride, 5-methoxy-N,N-dimethyltryptamine hydrogen oxalate, RU 24969 [methoxy-3- (1,2,3.6-tetrahydropyridin-4-yl)-1H-indole] and d-lysergic acid diethylamide. In contrast, the 5-HT1B/1C agonist, TFMPP m- trifluromethylphenylpiperazine HCl, and the 5-HT1C/2 agonist, DOI (+-)- 2,5-dimethoxy-4-iodophenyl-2-aminopropane HCI, were ineffective. The putative selective 5-HT1A antagonists, BMY 7378 [(8-[-[4-(2- ,ethoxyphenyl)-1-piperazinyl]ethyl]-8-azaspirol[4]- decane-7,9-dione-2- HCL] and spiperone, did not reduce MIA. Indeed, BMY 7378 blocked the ability of 8-OH-DPAT to antagonize MIA. Under the present conditions, agonists and antagonists at adrenergic and dopaminergic receptors did not attenuate MIA. These data show that, over a certain range of doses, the systemic administration of 8-OH-DPAT and other high efficacy 5-HT1A agonists functionally antagonizes the antinociceptive action of systemically applied morphine in a competitive-like manner. It is suggested that 5-HT1A receptors play an important role in the modulation of opioidergic antinociceptive mechanisms.

Volume 256, Issue 3, pp. 983-992, 03/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				S. G. Khasabov, S. D. Rogers, J. R. Ghilardi, C. M. Peters, P. W. Mantyh, and D. A. Simone Spinal Neurons that Possess the Substance P Receptor Are Required for the Development of Central Sensitization J. Neurosci., October 15, 2002; 22(20): 9086 - 9098. [Abstract] [Full Text] [PDF]

				H. S. Hain, J. K. Belknap, and J. S. Mogil Pharmacogenetic Evidence for the Involvement of 5-Hydroxytryptamine (Serotonin)-1B Receptors in the Mediation of Morphine Antinociceptive Sensitivity J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 444 - 449. [Abstract] [Full Text]

				L. A. Pini, G. Vitale, A. Ottani, and M. Sandrini Naloxone-Reversible Antinociception by Paracetamol in the Rat J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 934 - 940. [Abstract] [Full Text]